Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1816

Sort by

Sort Order Select

Journal Articles

Mammalian VPS45 orchestrates trafficking through the endosomal system

Laura Frey, Natalia Ziętara, Marcin Łyszkiewicz, Benjamin Marquardt, Yoko Mizoguchi, Monika I. Linder, Yanshan Liu, Florian Giesert, Wolfgang Wurst, Maik Dahlhoff, Marlon R. Schneider, Eckhard Wolf, Raz Somech, Christoph Klein

Blood (2021) 137 (14): 1932–1944.

https://doi.org/10.1182/blood.2020006871

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

To be, or not to be

Alessandro Maria Vannucchi

Blood (2020) 135 (19): 1617–1618.

https://doi.org/10.1182/blood.2020005363

Published: 2020

Journal Articles

Verruconis gallopava in a patient with myelofibrosis on ruxolitinib

Andrew Hsu, Veronica Ulici

Blood (2020) 135 (14): 1189.

https://doi.org/10.1182/blood.2020004799

Published: 2020

Journal Articles

Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation

Samuel A. Stoner, Ming Yan, Katherine Tin Heng Liu, Kei-Ichiro Arimoto, Takahiro Shima, Huan-You Wang, Daniel T. Johnson, Rafael Bejar, Catriona Jamieson, Kun-Liang Guan, Dong-Er Zhang

Blood (2019) 134 (20): 1730–1744.

https://doi.org/10.1182/blood.2019000170

Published: 2019

Includes: Supplemental data

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Megakaryocyte Ablation Ameliorates Bone Marrow Fibrosis By Reducing Myofibroblast Differentiation in a Mouse Model of Primary Myelofibrosis

Yutein Chung, PhD, Huiyan Jin, PhD, Claire Trasorras, Francina Gonzalez, Sang Hee Min, MD PhD

Blood (2019) 134 (Supplement_1): 2493.

https://doi.org/10.1182/blood-2019-132186

Published: 2019

Journal Articles

Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1 low Mutation

Barbara Bacci, PhD, Francesca Gobbo, Mariana Roccaro, Angelo Peli, PhD, Maria Zingariello, PhD, Fabrizio Martelli, PhD, Paola Verachi, Claudio Bardelli, PhD, Maria Mazzarini, Giuseppe Sarli, PhD, Anna Rita Migliaccio, PhD

Blood (2019) 134 (Supplement_1): 2336.

https://doi.org/10.1182/blood-2019-123994

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

Defective Autophagy in MPN Were Predominantly Detected in Megakaryocytes in Philadelphia Negative (Ph -) Myeloproliferative Neoplasm

Jen-Chin Wang, MD, Guanfang Shi, PhD, Karan Josan, MD, Preethi Ramachandran, Vladimir Gotlieb, Gardith Joseph, Sherif A. Nasr, MD

Blood (2019) 134 (Supplement_1): 5386.

https://doi.org/10.1182/blood-2019-127949

Published: 2019

Journal Articles

Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University

Yanika Jindamai, MD, Ekarat Rattarittamrong, MD, Arintaya Phrommintikul, MD, Lalita Yongsmith, MD, Thanawat Rattanathammethee, MD, Chatree Chai-Adisaksopha, MD PhD, Adisak Tantiworawit, MD, Lalita Norasetthada, MD

Blood (2019) 134 (Supplement_1): 5390.

https://doi.org/10.1182/blood-2019-126599

Published: 2019

Journal Articles

The Platelet Millionaire: A Rare Cause of Thrombocytosis in an Adolescent

Ritika Walia, MD, Theresa Sepulveda, MD, Sharon Wretzel, MD, Philip H Brandt, MD

Blood (2019) 134 (Supplement_1): 5391.

https://doi.org/10.1182/blood-2019-129278

Published: 2019

Journal Articles

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Paranagama, PhD, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 5385.

https://doi.org/10.1182/blood-2019-123833

Published: 2019

Journal Articles

Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line

Jie Zhou, Aibin Liang, PhD, Shaoguang Li, Wenjun Zhang, Jianfei FU, MD

Blood (2019) 134 (Supplement_1): 5394.

https://doi.org/10.1182/blood-2019-125434

Published: 2019

Journal Articles

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 5396.

https://doi.org/10.1182/blood-2019-130560

Published: 2019

Journal Articles

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Hsin-An Hou, Chien-Chin Lin, MD, Ming-Chung Kuo, MD, Shyuann-Yuh Lin, MD, Jyh-Pyng Gau, MD, Ming-Chung Wang, MD, Ming-Chih Chang, MD, Tsung-Chih Chen, MD, Su-Peng Yeh, MD, Yeu-Chin Chen, MD, Cih-En Huang, MD, Chieh-Wen Chen, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, MD, Lee-Yung Shih, MD

Blood (2019) 134 (Supplement_1): 5374.

https://doi.org/10.1182/blood-2019-129645

Published: 2019

Journal Articles

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Arafat Ali Farooqui, MD, Ahmad Anjum, MD, Muhammad Saad Farooqi, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Aqsa Ashraf, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5548.

https://doi.org/10.1182/blood-2019-122395

Published: 2019

Journal Articles

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Jamie Koprivnikar, MD, James K McCloskey, MD, Rena Feinman, PhD, Robert Korngold, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD

Blood (2019) 134 (Supplement_1): 5618.

https://doi.org/10.1182/blood-2019-132025

Published: 2019

Journal Articles

Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

Yanping Ji, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Guangyu Sun, Jian Wang, Zimin Sun

Blood (2019) 134 (Supplement_1): 5677.

https://doi.org/10.1182/blood-2019-130138

Published: 2019

Journal Articles

Efficacy and Safety Profile of Bortezomib Based Regimens for Treatment of Newly Diagnosed Amyloidosis: A Systematic Review of Literature

Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Hamza Hassan, MD MBBS, Adeela Mushtaq, MD, Ahmad Iftikhar, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Zunairah Shah, MBBS, Ahmed Ibrahim, Adnan Basheer, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5583.

https://doi.org/10.1182/blood-2019-127190

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mammalian VPS45 orchestrates trafficking through the endosomal system

To be, or not to be

Verruconis gallopava in a patient with myelofibrosis on ruxolitinib

Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Megakaryocyte Ablation Ameliorates Bone Marrow Fibrosis By Reducing Myofibroblast Differentiation in a Mouse Model of Primary Myelofibrosis

Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1 low Mutation

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

Defective Autophagy in MPN Were Predominantly Detected in Megakaryocytes in Philadelphia Negative (Ph -) Myeloproliferative Neoplasm

Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University

The Platelet Millionaire: A Rare Cause of Thrombocytosis in an Adolescent

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

Efficacy and Safety Profile of Bortezomib Based Regimens for Treatment of Newly Diagnosed Amyloidosis: A Systematic Review of Literature

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only